Vanguard Group’s Krystal Biotech KRYS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $685M | Sell |
2,778,845
-13,363
| -0.5% | -$2.81M | 0.01% | 868 |
|
|
2025
Q3 | $493M | Sell |
2,792,208
-30,680
| -1% | -$4.59M | 0.01% | 1079 |
|
|
2025
Q2 | $388M | Sell |
2,822,888
-2,394
| -0.1% | -$352K | 0.01% | 1171 |
|
|
2025
Q1 | $509M | Sell |
2,825,282
-53,169
| -2% | -$8.94M | 0.01% | 982 |
|
|
2024
Q4 | $451M | Buy |
2,878,451
+28,707
| +1% | +$5.09M | 0.01% | 1093 |
|
|
2024
Q3 | $519M | Sell |
2,849,744
-19,392
| -0.7% | -$3.74M | 0.01% | 1026 |
|
|
2024
Q2 | $527M | Buy |
2,869,136
+436,357
| +18% | +$73.3M | 0.01% | 962 |
|
|
2024
Q1 | $433M | Sell |
2,432,779
-2,995
| -0.1% | -$416K | 0.01% | 1086 |
|
|
2023
Q4 | $302M | Buy |
2,435,774
+35,632
| +1% | +$3.95M | 0.01% | 1283 |
|
|
2023
Q3 | $278M | Buy |
2,400,142
+693,852
| +41% | +$84.7M | 0.01% | 1256 |
|
|
2023
Q2 | $200M | Buy |
1,706,290
+504,060
| +42% | +$51.5M | ﹤0.01% | 1475 |
|
|
2023
Q1 | $96.3M | Buy |
1,202,230
+14,120
| +1% | +$1.11M | ﹤0.01% | 1853 |
|
|
2022
Q4 | $94.1M | Buy |
1,188,110
+91,978
| +8% | +$6.83M | ﹤0.01% | 1835 |
|
|
2022
Q3 | $76.4M | Buy |
1,096,132
+26,844
| +3% | +$1.94M | ﹤0.01% | 1955 |
|
|
2022
Q2 | $70.2M | Buy |
1,069,288
+17,843
| +2% | +$1.11M | ﹤0.01% | 2019 |
|
|
2022
Q1 | $70M | Buy |
1,051,445
+27,835
| +3% | +$1.74M | ﹤0.01% | 2130 |
|
|
2021
Q4 | $71.6M | Buy |
1,023,610
+134,952
| +15% | +$7.86M | ﹤0.01% | 2155 |
|
|
2021
Q3 | $46.4M | Buy |
888,658
+42,303
| +5% | +$2.5M | ﹤0.01% | 2404 |
|
|
2021
Q2 | $57.6M | Buy |
846,355
+15,944
| +2% | +$1.11M | ﹤0.01% | 2291 |
|
|
2021
Q1 | $64M | Buy |
830,411
+91,273
| +12% | +$6.64M | ﹤0.01% | 2177 |
|
|
2020
Q4 | $44.3M | Buy |
739,138
+6,100
| +0.8% | +$305K | ﹤0.01% | 2264 |
|
|
2020
Q3 | $31.6M | Buy |
733,038
+8,385
| +1% | +$364K | ﹤0.01% | 2252 |
|
|
2020
Q2 | $30M | Buy |
724,653
+86,605
| +14% | +$4.17M | ﹤0.01% | 2236 |
|
|
2020
Q1 | $27.6M | Buy |
638,048
+23,414
| +4% | +$1.22M | ﹤0.01% | 2146 |
|
|
2019
Q4 | $34M | Buy |
614,634
+19,290
| +3% | +$946K | ﹤0.01% | 2287 |
|
|
2019
Q3 | $20.7M | Buy |
595,344
+98,465
| +20% | +$4.4M | ﹤0.01% | 2478 |
|
|
2019
Q2 | $20M | Buy |
496,879
+143,409
| +41% | +$4.69M | ﹤0.01% | 2509 |
|
|
2019
Q1 | $11.6M | Buy |
353,470
+16,705
| +5% | +$394K | ﹤0.01% | 2747 |
|
|
2018
Q4 | $7M | Buy |
336,765
+163,287
| +94% | +$3.42M | ﹤0.01% | 2938 |
|
|
2018
Q3 | $3.05M | Buy |
173,478
+20,100
| +13% | +$337K | ﹤0.01% | 3395 |
|
|
2018
Q2 | $2.28M | Buy |
153,378
+4,269
| +3% | +$48K | ﹤0.01% | 3460 |
|
|
2018
Q1 | $1.5M | Buy |
149,109
+75,009
| +101% | +$739K | ﹤0.01% | 3546 |
|
|
2017
Q4 | $779K | Buy |
+74,100
| New | +$743K | ﹤0.01% | 3665 |
|
Other funds holding KRYS
ACA
SCM
RG
HRCM
Vanguard Group's KRYS Position: Q4 2025 in Review
Vanguard Group reduced its Krystal Biotech (KRYS) stake by 0.48% in Q4 2025, selling an estimated $2.81M and leaving 2,778,845 shares worth $685M. The position accounts for 0.01% of the portfolio, ranked #868.
Vanguard Group first reported a position in KRYS in Q4 2017 and has held it in 33 quarters since. 334 funds tracked by Wall St. Rank hold KRYS as of Q4 2025.
- Vanguard Group held 2,778,845 shares of Krystal Biotech worth $685M as of Q4 2025.
- Vanguard Group sold 13,363 Krystal Biotech shares in Q4 2025, an estimated $2.81M.
- Krystal Biotech made up 0.01% of Vanguard Group's portfolio in Q4 2025, its #868 holding.
- Vanguard Group first reported a position in Krystal Biotech in Q4 2017 and has held it in 33 quarters since.
- 334 funds tracked by Wall St. Rank held Krystal Biotech as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.